Beijing Continent Pharmaceutical Co, Ltd.

This study tests a drug called hydronidone to see if it can stop or slow liver scarring (fibrosis) in people with chronic hepatitis B. About 1,200 adults aged 18-65 will take either hydronidone or a placebo, along with standard antiviral therapy, for up to 5 years. The goal is to…

This early-stage study looks at how a new drug for liver scarring (hydronidone) interacts with four standard hepatitis B medications in 64 healthy adults. The goal is to measure drug levels in the blood and check for any harmful interactions. Results will help doctors prescribe t…

This early-stage study tests a higher dose of the drug hydronidone in 138 healthy Chinese adults. Researchers want to see how the body absorbs and processes the drug, and whether it is safe. This is not a treatment study; it gathers information to support future research on liver…

This study looks at how a drug called Hydronidone is absorbed, broken down, and removed from the body. It involves 8 healthy Chinese men aged 18 to 50. The goal is to understand the drug's journey, not to treat any disease. Results will help doctors use the drug more safely for c…

This study looks at how the body handles a single dose of hydronidone in people with different levels of liver function. It includes 30 adults with either normal liver function or varying degrees of liver impairment. The goal is to understand how liver health affects drug levels …